Citations

Showing 10 of 107969 citations.

TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
Gessain, Grégoire , Anzali, Ahmed-Amine , Lerousseau, Marvin , Mulder, Kevin , Bied, Mathilde , Aupérin, Anne , Stockholm, Daniel , Signolle, Nicolas , Sassi, Farah , Costa, Maria Eugénia Marques Da , Sayadi, Alexandre , Weidner, Daniela , Blampey, Quentin , Nakkireddy, Sumanth Reddy , Dutertre, Charles‐Antoine , Walter, Thomas , Marhic, Alix , Guerlain, Joanne , Casiraghi, Odile , Marques Da Costa, Maria Eugenia , Marchais, Antonin , Sayadi, Alexandre , Weidner, Daniela , Uderhardt, Stefan , Blampey, Quentin , Nakkireddy, Sumanth Reddy , Broutin, Sophie , Dutertre, Charles-Antoine , Busson, Pierre , Walter, Thomas , Marhic, Alix , Moya-Plana, Antoine , Guerlain, Johanne , Breuskin, Ingrid , Casiraghi, Odile , Gorphe, Philippe , Classe, Marion , Scoazec, Jean-Yves , Blériot, Camille , Ginhoux, Florent , Auperin, Anne , Uderhardt, Stefan , Moya‐Plana, Antoine

Mayo Clinic

Cancer Discovery | September 13, 2024 | Volume: 14 | Issue: 12 | Pages: 2352-2366

10.1158/2159-8290.cd-24-0018 | PMID 39270324 Get It

Abstract Patients with head and neck squamous cell carcinomas (HNSCC) often have poor outcomes due to suboptimal risk management and treatment strategies; yet integrating novel prognostic biomarkers into clinical practice is challenging. Here, we report the presence of multinucleated giant cells (MGC)—a type of macrophages—in tumors from patients with HNSCC, which are associated with a favorable prognosis in treatment-naive and preoperative chemotherapy–treated patients. Importantly, MGC density increased in tumors following preoperative therapy, suggesting a role of these cells in the antitumoral response. To enable clinical translation of MGC density as a prognostic marker, we developed a deep-learning model to automate its quantification on routinely stained pathological whole slide images. Finally, we used spatial transcriptomic and proteomic approaches to describe the MGC-related tumor microenvironment and observed an increase in central memory CD4 T cells. We defined an MGC-specific signature resembling to TREM2-expressing mononuclear tumor-associated macrophages, which colocalized in keratin tumor niches. Significance: Novel individual biomarkers are needed to guide therapeutic decisions for patients with head and neck cancer. We report for the first time, granulomas of TREM2-expressing multinucleated giant macrophages in keratin-rich tumor niches, as a biomarker of favorable prognosis and developed a deep-learning model to automate its quantification on routinely stained pathological slides.
When to Start Computer-Based Auditory Training After Cochlear Implantation: Effects on Quality of Life and Speech Recognition
Dornhoffer, James R. , Shannon, C. E. G., Hernandez-Herrara, Gabriel A., Schvartz‐Leyzac, Kara C. , Dubno, Judy R. , Hernandez-Herrera, Gabriel A. , Hernandez Herrera, Gabriel A , Shannon, Christian, McRackan, Theodore R.

Mayo Clinic

Otology & Neurotology | September 13, 2024 | Volume: 45 | Issue: 9 | Pages: 1023-1029

10.1097/mao.0000000000004318 | PMID 39264920 Get It

Objective Computer-based auditory training (CBAT) has been shown to improve outcomes in adult cochlear implant (CI) users. This study evaluates in new CI users whether starting CBAT within 3 months of activation or later impacts CI outcomes. Study Design Prospective natural experiment. Setting Tertiary academic medical center. Patients Sixty-five new adult CI users. Interventions CBAT use over the first-year postactivation. Main Outcome Measures Speech recognition scores and CIQOL-35 Profile score improvements between CI recipients who started CBAT resources early (<3 mo) and late (3–12 mo) postactivation. Results A total of 43 CI recipients started using CBAT within 3 months postactivation (early) and 22 after 3 months (late). Patients who used CBAT within 3 months postactivation showed significantly greater improvement in consonant-nucleus-consonant words (CNCw) (48.3 ± 24.2% vs 27.8 ± 24.9%; d = 0.84), AzBio Sentences in quiet (55.1 ± 28.0% vs 35.7 ± 36.5%; d = 0.62), and CIQOL-35 listening domain scores (18.2 ± 16.3 vs 6.9 ± 12.9, d = 0.73 [0.023, 1.43]), at 3 months postactivation, compared to those who had not yet initiated CBAT. However, by 12 months postactivation, after which all CI recipients had started CBAT, there were no differences observed between patients who started CBAT early or late in speech recognition scores (CNCw: d = 0.26 [−0.35, 0.88]; AzBio: d = 0.37 [−0.23, 0.97]) or in any CIQOL global or domain score (d-range = 0.014–0.47). Conclusions Auditory training with self-directed computer software (CBAT) may yield speech recognition and quality-of-life benefits for new adult CI recipients. While early users showed greater improvement in outcomes at 3 months postactivation than users who started later, both groups achieved similar benefits by 12 months postactivation.
Impact of Policy Changes and Program Support on Family Planning Goals among Plastic Surgery Trainees
Gates-Tanzer, Lauren, Millesi, Elena , Vijayasekaran, Aparna , Harless, Christin A., Harless, Christin, Gates-Tanzer, Lauren

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 13, 2024 | Volume: 12 | Issue: 9 | Pages: e6158

10.1097/gox.0000000000006158 | PMID 39281088 Get It

Background: In 2020, the American Board of Plastic Surgeons announced an update in the leave policy for plastic surgery trainees, extending personal leave to 12 weeks without delay in graduation. Simultaneously, the Accreditation Council for Graduate Medical Education announced their update in lactation policy. This study sought to understand the influence of the policy change on plastic surgery trainees’ goals for family planning and lactation. Methods: An online 32-question survey was developed to evaluate plastic surgery trainees’ perceptions of family planning and perceived program support in the United States. The survey was approved by the American Council of Academic Plastic Surgeons Research Committee and sent out to a total of 216 plastic surgery programs. Results: One hundred thirty plastic surgery trainees completed the survey. Most respondents were women, between the ages of 30 and 34 years, and married. Forty-five (34.6%) respondents or their partners had experienced pregnancy or live birth during their training. More than 70% did not feel that they had adequate time for leave. Female trainees faced more barriers than men, including having a partner in training, concern for their pregnancy, and burdening their co-residents during leave. The majority stated that their decision to apply to plastic surgery residency was influenced by program support for family planning compared with policy changes. Conclusions: This survey highlighted that the new policies benefit trainees who consider starting a family during training. Despite this, there are still challenges that need to be addressed to help foster a fair environment for trainees to work and have a family.
Increased Risk and Unique Clinical Course of Patient Safety Indicator-3 Pressure Injuries Among COVID-19 Hospitalized Patients
Cowart, Jennifer B. , FRÍAS, JORGE SINCLAIR DE , Pollock, Benjamin D. , Knepper, Camille, Sammon, Nora, Jonna, Sadhana , Singh, Trisha, Bhakta, Shivang , Olivero, Lorenzo , Ochoa, Shari A. , Ramar, Kannan , Singh, Tarun D. , De Frías, Jorge Sinclair, Pollock, Benjamin D , Knepper, Camille, Singh, Trisha, Franco, Pablo Moreno

Mayo Clinic

Journal of Patient Safety | September 13, 2024 | Volume: 20 | Issue: 8 | Pages: e128-e134

10.1097/pts.0000000000001276 | PMID 39269226 Get It

Background The COVID-19 pandemic introduced unique challenges to healthcare systems, particularly in relation to patient safety and adverse events during hospitalization. There is limited understanding of COVID-19’s association with some patient safety indicators (PSIs). Objectives This study aimed to investigate the impact of COVID-19 infection on the rate of PSI-3 events and its implications on quality metrics. We compared PSI-3 event rates between COVID-19–infected and uninfected patients and examined the clinical characteristics of COVID-19 patients experiencing PSI-3 events. Methods This is a retrospective study at Mayo Clinic hospitals between January 2020 and February 2022, analyzing patients meeting PSI-3 denominator eligibility criteria. PSI-3 events were identified using AHRQ WinQI software. Patients were categorized based on COVID-19 status. Patient demographics, characteristics, and PSI-3 rates were compared. A case series analysis described clinical details of COVID-19 patients with PSI-3 events. Results Of 126,781 encounters meeting PSI-3 criteria, 8674 (6.8%) had acute COVID-19 infection. COVID-19–infected patients were older, more likely to be male, non-white, and had private insurance. PSI-3 rates were significantly higher in COVID-19 patients (0.21% versus 0.06%, P < 0.0001), even after risk adjustment (adjusted risk ratio, 3.24, P < 0.0001). The case series of 17 COVID-19 patients with PSI-3 events showed distinctive clinical characteristics, including higher medical device–related pressure injuries, and greater predisposition for head, face, and neck region. Conclusions Acute COVID-19 infection correlates with higher PSI-3 event rates. Current quality indicators may require adaptation to address the pandemic’s complexities and impact on patient safety. Further research is needed to comprehensively understand the intricate relationship between COVID-19 and patient outcomes.
The Microbiome side of OBGYN
Walther-António, Marina

Mayo Clinic

No container title available | September 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52843/cassyni.1xq3pc Get It

We will do a recap of our microbiome work in Obstetrics and Gynecology, starting with our findings in healthy populations and natural variation. Then transitioning to healthy obstetrics and preterm labor. And wrapping up with gynecologic cancers, particularly endometrial and ovarian cancer.
Shifting Paradigms in Graves' Disease Management: An Updated Survey of Clinical Practice and Emerging Trends
Kawkgi, Omar El

Mayo Clinic

Clinical Thyroidology® | September 13, 2024 | Volume: 36 | Issue: 9 | Pages: 322-325

10.1089/ct.2024;36.322-325 Get It

Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
McCoy, Rozalina G. , Swarna, Kavya, Deng, Yihong, Mickelson, Mindy M. , McCoy, Rozalina Grubina , Neumiller, Joshua J. , Polley, Eric C. , Deng, Yihong , Mickelson, Mindy M , Herrin, Jeph

Mayo Clinic

Clinical Diabetes | September 13, 2024 | Volume: 43 | Issue: 1 | Pages: 59-70

10.2337/cd24-0007 | PMID 39829688 Get It

In this emulated comparative effectiveness target trial of glucagon-like peptide 1 (GLP-1) receptor agonist, sodium–glucose cotransporter 2 (SGLT2) inhibitor, dipeptidyl peptidase 4 (DPP-4) inhibitor, and sulfonylurea therapy among adults with type 2 diabetes at moderate cardiovascular disease risk, sulfonylurea use was associated with a significantly higher risk of hypoglycemia requiring emergency department or hospital care than treatment with DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors. This consideration can guide the choice of glucose-lowering therapy in this highly prevalent patient population, in whom avoidance of hypoglycemia is important, yet among whom the risk of severe hypoglycemia has not been examined previously.
Esophageal lymphocytosis: exploring the knowns and unknowns of this pattern of esophageal injury
Coady, Laoise, Sheahan, Kieran , Brown, Ian , Gill, Anthony J. , Kumarasinghe, Priyanthi , Kushima, Ryoji , Lauwers, Gregory Y. , Pai, Rish K. , Shepherd, Neil A. , Slavík, Tomáš , Langner, Cord , Brown, Ian S , Carneiro, Fátima , Srivastava, Amitabh

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | September 13, 2024 | Volume: 18 | Issue: 9 | Pages: 529-539

10.1080/17474124.2024.2385493 | PMID 39268773 Get It

Bioengineering MSCs for untapped therapeutic potential
Sirpilla, Olivia , Kenderian, Saad S. , Kenderian, Saad Sirop , Sirpilla, Olivia L

Mayo Clinic

Immunotherapy | September 13, 2024 | Volume: 16 | Issue: 14-15 | Pages: 907-911

10.1080/1750743x.2024.2390819 | PMID 39268677 Get It